Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors

Latin American Cooperative Oncology Group (LACOG)

Status and phase: Completed; Phase 2

Conditions: Neuroendocrine Tumors

Treatments: Other: 99m Tc - HYNIC -TOC EDDA and 111In - DTPA-octreotide

Study type: Interventional

Funder types: Other

Identifiers

NCT02691078

LACOG 0214

Details and patient eligibility

About

Evaluation of the properties of the image capture test using 99m Tc - HYNIC -TOC EDDA (octreotide labeled with 99mTc) for the diagnosis of neuroendocrine tumors compared to the 111In - DTPA-octreotide.

Enrollment: 15 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with histological diagnosis of neuroendocrine tumors
• Patients with indication for the staging exam with 11In
• Patients diagnosed in any tumor stage
• Patients with > 18 years
• Male and female patients
• Patients not receiving somatostatin analogues for at least 1 month before image capturing

Exclusion criteria

• Pregnant women
• Patients with previous tumor resection of the primary tumor without metastatic disease

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

15 participants in 1 patient group

Adult patients with neuroendocrine tumors

Experimental group

Treatment:

Other: 99m Tc - HYNIC -TOC EDDA and 111In - DTPA-octreotide